Advertisement

Topics

Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

13:52 EST 13 Nov 2017 | SCRIP

Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said...

      

Related Stories

 

Original Article: Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

NEXT ARTICLE

More From BioPortfolio on "Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...